The long-term tolerability of linezolid is low because of mitochondrial toxicity, whereas tedizolid may represent a better option for suppressive therapy. We report a first presumed case of tedizolid-associated optic neuropathy after a very prolonged (18-month) intake and believe that screening for optic neuropathy should be considered for patients undergoing tedizolid suppression.
Keywords: optic neuropathy; oxazolidinones; suppressive therapy; tedizolid; vascular graft infections.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.